Cardiovascular risk profile in individuals initiating treatment for overactive bladder – Challenges and learnings for comparative analysis using linked claims and electronic medical record databases

Brief Report

(2016) Benjamin F. Arnold et al.   EPIDEMIOLOGY

Real-World Patterns of Care for the Overactive Bladder Syndrome in the United States

(2016) Howard B. Goldman et al.   UROLOGY

Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment

(2015) E. Ann Gormley et al.   JOURNAL OF UROLOGY

Stage 2 hypertension: predictors of failure to achieve blood pressure control and the impact of adding one additional antihypertensive class

(2015) Christopher G. Rowan et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis

(2015) Mark H. Rozenbaum et al.   VACCINE

Retrospective Study Of Utilization Patterns Of Overactive Bladder Therapy In Men In A Commercially Insured Population: The Early Us Mirabegron Experience

(2015) D Ng et al.   VALUE IN HEALTH

Short- and Long-Term Major Cardiovascular Adverse Events in Carotid Artery Interventions: A Nationwide Population-Based Cohort Study in Taiwan

(2015) Ming-Lung Tsai et al.   PLoS One

Long-Term Patterns of Use and Treatment Failure With Anticholinergic Agents for Overactive Bladder

(2013) Michael B. Chancellor et al.   CLINICAL THERAPEUTICS

Prespecified Falsification End Points

(2013) Vinay Prasad et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Comparison of Transradial Versus Transfemoral Percutaneous Coronary Intervention in Routine Practice

(2013) Neil J. Wimmer et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

(2013) Sender Herschorn et al.   UROLOGY

Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study

(2013) Bradley Curtis et al.   JOURNAL OF MEDICAL ECONOMICS

Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings

(2013) Derek Weycker et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

(2012) Christopher R. Chapple et al.   EUROPEAN UROLOGY

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

(2012) Vik Khullar et al.   EUROPEAN UROLOGY

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Accuracy of Blood Pressure Measurements Reported in an Electronic Medical Record During Routine Primary Care Visits

(2011) Paul A. Fishman et al.   Journal of Clinical Hypertension

Herpes Zoster and Postherpetic Neuralgia Surveillance Using Structured Electronic Data

(2011) Michael Klompas et al.   MAYO CLINIC PROCEEDINGS

Confounding Control in Healthcare Database Research

(2010) M. Alan Brookhart et al.   MEDICAL CARE

Prevalence of Obesity, Type II Diabetes Mellitus, Hyperlipidemia, and Hypertension in the United States: Findings from the GE Centricity Electronic Medical Record Database

(2010) Albert G. Crawford et al.   Population Health Management

Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting

(2009) Carrie McAdam-Marx et al.   CLINICAL THERAPEUTICS

Weight Change in Diabetes and Glycemic and Blood Pressure Control

(2008) A. C. Feldstein et al.   DIABETES CARE